<DOC>
	<DOCNO>NCT02694822</DOCNO>
	<brief_summary>This open-label , Phase 1 , multicenter study evaluate safety , PK , PD anti-CTLA-4 human monoclonal antibody ( AGEN1884 ) estimate MTD subject advance refractory cancer . The study consist 3+3 dose escalation cohort start near minimally anticipate biologic effect level ( MABEL ) dose follow MTD expansion cohort immunotherapy-experienced immunotherapy-naïve subject .</brief_summary>
	<brief_title>AGEN-1884 , Anti-CTLA-4 Antibody , Advanced Solid Cancers</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>1 . Sign inform consent . 2 . ≥18 year age . 3 . Histological cytological diagnosis solid cancer lymphoma consider incurable without therapy establish benefit . Biopsy necessary subject know prior diagnosis clinical radiographic evidence recurrence . 4 . Eastern Cooperative Oncology Group score 0 1 ( Appendix B ) . 5 . Life expectancy ≥12 week . 6 . Adequate cardiac function ( ≤New York Heart Association [ NYHA ] Class II ) ( Appendix C ) . 7 . Adequate organ function define absolute neutrophil count ≥1,500×106/L , absolute lymphocyte count ≥500/mm3 , platelet count ≥100,000×106/mm3 . Adequate liver function define aspartate aminotransferase alanine aminotransferase ≤2.5× upper limit institutional normal , bilirubin ≤1.5 mg/dL 25 µmol/L . Adequate renal function define blood urea nitrogen serum creatinine ≤1.5 mg/dL 130 µmol/L . 8 . Female subject childbearing potential fertile male subject must agree use adequate contraception abstain sexual activity time consent 90 day end study drug . Adequate contraception include condom contraceptive foam ; oral , implantable , injectable contraceptive ; contraceptive patch ; intrauterine device ; diaphragm spermicidal gel ; sexual partner surgically sterilize postmenopausal . Exclusion Criteria 1 . Other malignancy treat within last 5 year , except situ cervix carcinoma nonmelanoma skin cancer . 2 . Other form ( ) antineoplastic therapy anticipate period study . 3 . Previous severe hypersensitivity reaction another monoclonal antibody , colitis pneumonitis require treatment steroid , history interstitial lung disease . 4 . History acute diverticulitis , intraabdominal abscess , gastrointestinal obstruction , abdominal carcinomatosis . 5 . Primary secondary immunodeficiency ( include immunosuppressive disease , autoimmune disease [ include autoimmune endocrinopathies , hypothyroidism , insulin dependent diabetes mellitus ] , usage immunosuppressive medication ) . 6 . Subjects know history human immunodeficiency virus 1 2 , human T lymphotropic virus 1 , hepatitis B virus , active hepatitis C virus . 7 . Subjects history connective tissue disorder . 8 . Receipt anticancer medication investigational drug within follow interval first administration study drug : 1 . ≤14 day chemotherapy , target small molecule therapy , radiation therapy . Subjects must also radiation pneumonitis result treatment , participate study chronic corticosteroid radiation pneumonitis . A 1week washout permit palliative radiation noncentral nervous system ( CNS ) disease sponsor approval . Note : Bisphosphonates denosumab permitted medication . 2 . ≤28 day prior immunotherapy . No prior therapy check point inhibitor , costimulatory agonist immunomodulatory agent allow . 3 . ≤28 day prior monoclonal antibody use anticancer therapy exception denosumab . 4 . ≤28 day prior systemic corticosteroid therapy . 5 . ≤7 day immunesuppressivebased treatment reason . Note : Use inhale topical corticosteroid use radiographic procedure permit . Note : The use physiologic corticosteroid replacement therapy may approve consultation sponsor . 6 . ≤28 day 5 halflives ( whichever longer ) first dose investigational study drug device . 9 . Has recover Grade ≤1 toxic effect prior therapy and/or complication prior surgical intervention start therapy . Note : Subjects Grade ≤2 neuropathy exception may enroll . 10 . Uncontrolled infection serious medical illness . 11 . History presence abnormal ECG , investigator 's opinion , clinically meaningful . Screening correct QT ( QTc ) interval &gt; 470 msec exclude ( correct Fridericia ) . If single QTc &gt; 470 millisecond , subject may enroll average QTc 3 ECGs &lt; 470 millisecond . For subject intraventricular conduction delay ( QRS interval &gt; 120 millisecond ) , JTc interval may use place QTc sponsor approval . The JTc must &lt; 340 millisecond JTc use place QTc . Subjects leave bundle branch block exclude . Note : QTc prolongation due pacemaker may enroll JTc normal medical monitor approval . 12 . Any medication know prolong QTc interval ( Appendix G ) . 13 . Any medical condition , opinion investigator , would preclude use AGEN1884 , include AGEN1884 hypersensitivity . 14 . Women pregnant breastfeeding . 15 . Concurrent participation investigational drug trial . 16 . Subjects CNS tumor metastases nonCNS tumor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>